Abstract
OS2.7 An open-labelled, randomized phase II study in patients with recurrent Glioblastoma Multiforme comparing progression free survival of ALECSAT (Autologous lymphoid effector cells specific against tumour-cells) versus Bevacizumab/Irinotecan
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have